Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a toll-like 7 receptor agonist in mice

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1179-1185

  Benson, Neil ^a   De Jongh, Joost ^b   Duckworth, Jonathan D ^a   Jones, Hannah M ^a   Pertinez, Henry E ^c   Rawal, Jaiessh K ^a   Van Steeg, Tamara J ^b   Van Der Graaf, Piet H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b LAP and P Consultants BV   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[9 BENZYL 8 HYDROXY 2 (2 METHOXYETHOXY) ADENINE; ALPHA INTERFERON; BIOLOGICAL MARKER; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; TREATMENT RESPONSE;

ADENINE; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MICE; MODELS, ANIMAL; TOLL-LIKE RECEPTOR 7;

EID: 77149134610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00551-09     Document Type: Article

References (40)

1. Arany, I., S. K. Tyring, M. A. Stanley, M. A. Tomai, R. L. Miller, M. H. Smith, D. J. McDermott, and H. B. Slade. 1999. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 43:55-63.
2. Averett, D. R., S. P. Fletcher, W. Li, S. E. Webber, and J. R. Appleman. 2007. The pharmacology of endosomal TLR agonists in viral disease. Biochem. Soc. Trans. 35:1468-1472.
3. Beal, S. L., and L. B. Sheiner. 1999. NONMEM user's guide. University of California at San Francisco, San Francisco.
4. Bekkering, F. C., J. T. Brouwer, B. E. Hansen, and S. W. Schalm. 2001. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. J. Hepatol. 34:435-440.
5. Danhof, M., E. C. de Lange, O. E. Della Pasqua, B. A. Ploeger, and R. A. Voskuyl. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PKPD) modeling in translational drug research. Trends Pharmacol. Sci. 29:186-191.
6. Di Bisceglie, A. M. 1998. Hepatitis C. Lancet 351:351-355.
7. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303:1529-1531.
8. Dunne, A., and L. O'Neill. 2005. Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. 579:3330-3335.
9. Fletcher, S., K. Steffy, and D. Averett. 2006. Masked oral prodrugs of Tolllike receptor 7 agonists: a new approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs 7:702-708.
10. Fried, M. W. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:S237-S244.
11. Gobburu, J. V., H. Agerso, W. J. Jusko, and L. Ynddal. 1999. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm. Res. 16:1412-1416.
12. Hammerbeck, D. M., G. R. Burleson, C. J. Schuller, J. P. Vasilakos, M. Tomai, E. Egging, F. R. Cochran, S. Woulfe, and R. L. Miller. 2007. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 73:1-11.
13. Hirota, K., K. Kazaoka, I. Niimoto, H. Kumihara, H. Sajiki, Y. Isobe, H. Takaku, M. Tobe, H. Ogita, T. Ogino, S. Ichii, A. Kurimoto, and H. Kawakami. 2002. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J. Med. Chem. 45:5419-5422.
14. Honda, K., Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. Taniguchi. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040.
15. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777.
16. Horsmans, Y., T. Berg, J. P. Desager, T. Mueller, E. Schott, S. P. Fletcher, K. R. Steffy, L. A. Bauman, B. M. Kerr, and D. R. Averett. 2005. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:724-731.
17. Hua, J., M. J. Liao, and A. Rashidbaigi. 1996. Cytokines induced by Sendai virus in human peripheral blood leukocytes. J. Leukoc. Biol. 60:125-128.
18. Isobe, Y., A. Kurimoto, M. Tobe, K. Hashimoto, T. Nakamura, K. Norimura, H. Ogita, and H. Takaku. 2006. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J. Med. Chem. 49:2088-2095.
19. Jezequel, S. G. 1994. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J. Pharm. Pharmacol. 46:196-199.
20. Kola, I., and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-715.
21. Kurimoto, A., T. Ogino, S. Ichii, Y. Isobe, M. Tobe, H. Ogita, H. Takaku, H. Sajiki, K. Hirota, and H. Kawakami. 2004. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 12:1091-1099.
22. Lalonde, R. L., K. G. Kowalski, M. M. Hutmacher, W. Ewy, D. J. Nichols, P. A. Milligan, B. W. Corrigan, P. A. Lockwood, S. A. Marshall, L. J. Benincosa, T. G. Tensfeldt, K. Parivar, M. Amantea, P. Glue, H. Koide, and R. Miller. 2007. Model-based drug development. Clin. Pharmacol. Ther. 82:21-32.
23. Langdon, G., J. D. Davis, L. M. McFadyen, M. Dewhurst, N. S. Brunton, J. K. Rawal, P. H. Van der Graaf, and N. Benson. 2009. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent, and the potential application. Br. J. Clin. Pharmacol. [Epub ahead of print.] doi:10.1111/1365-2125.2009.03594.x.
24. Lee, J., C. C. Wu, K. J. Lee, T. H. Chuang, K. Katakura, Y. T. Liu, M. Chan, R. Tawatao, M. Chung, C. Shen, H. B. Cottam, M. M. Lai, E. Raz, and D. A. Carson. 2006. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 103:1828-1833.
25. Littman, B. H., L. Di Mario, M. Plebani, and F. M. Marincola. 2007. What's next in translational medicine? Clin. Sci. (Lond.) 112:217-227.
26. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
27. Mordenti, J. 1986. Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028-1040.
28. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
29. Nuwer, M. R., E. De Clercq, and T. C. Merigan. 1971. Interferon clearance rate decreased after repeated injections. J. Gen. Virol. 12:191-194.
30. Ploeger, B. A., P. H. van der Graaf, and M. Danhof. 2009. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab. Pharmacokinet. 24:3-15.
31. Powers, K. A., N. M. Dixit, R. M. Ribeiro, P. Golia, A. H. Talal, and A. S. Perelson. 2003. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin. Liver Dis. 23(Suppl. 1):13-18.
32. Schoemaker, R. C., and A. F. Cohen. 1996. Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42:283-290.
33. Shirakawa, K., E. Muso, F. Nogaki, M. Maeda, T. Kawamura, T. Ono, M. Yoshimoto, K. Uno, T. Kishida, and S. Sasayama. 2002. Correlation between the severity of clinicopathological parameters and whole blood interferonalpha production capacity in active phase IgA nephropathy patients. Nephron 90:24-30.
34. Thomas, A., C. Laxton, J. Rodman, N. Myangar, N. Horscroft, and T. Parkinson. 2007. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob. Agents Chemother. 51:2969-2978.
35. Tummino, P. J., and R. A. Copeland. 2008. Residence time of receptorligand complexes and its effect on biological function. Biochemistry 47:5481-5492.
36. Uematsu, S., and S. Akira. 2007. Toll-like receptors and type I interferons. J. Biol. Chem. 282:15319-15323.
37. Vergu, E., A. Mallet, and J.-L. Golmard. 2004. Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection. J. Antimicrob. Chemother. 53:140-143.
38. Witt, P. L., P. S. Ritch, D. Reding, T. L. McAuliffe, L. Westrick, S. E. Grossberg, and E. C. Borden. 1993. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53:5176-5180.
39. World Health Organization. 2000. Hepatitis C-global prevalence (update). Wkly. Epidemiol. Rec. 75:18-19.
40. Yassen, A., E. Olofsen, J. Kan, A. Dahan, and M. Danhof. 2007. Animal-tohuman extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin. Pharmacokinet. 46:433-447.